Greatview Aseptic Packaging Company Limited

The wide revenue guidance range (RMB731.8M–RMB990.1M) leaves room for a less severe outcome, and the company's low valuation multiples — Price/Sales of 0.88 and Price/Book of 1.05 — suggest the market may already be pricing in the worst-case scenario, offering potential upside.

The company's own board disclosed a net profit collapse of 87.7%–95.9% in H1 2026, driven by lower-priced export orders routed through International Business subsidiaries, reduced order volumes, and thinner gross margins — pointing to deep structural deterioration rather than a one-off setback.

Despite the prolonged trading suspension since February 2025, the company continues to propose cash dividends — with a final ordinary cash dividend payable in September 2026 — and retains a trailing dividend yield of 3.96%, signalling that the board is attempting to maintain shareholder returns.

Shares have remained suspended since 19 February 2025 with no resumption date disclosed, and the inability to recognise investment profits from Greatview Holdings International Limited due to a pending court process reflects unresolved governance and accounting disputes that create significant uncertainty.

The global aseptic processing and packaging market — estimated at USD 57.5 billion in 2025 and growing at a 7.5% CAGR — presents a strong structural tailwind, driven by rising demand for shelf-stable dairy products, eco-friendly materials, and intelligent packaging innovations that Greatview is positioned within.

With revenue already down as much as 27.3% year-on-year in H1 2026 and profit down up to 96%, Greatview's internal operational and accounting challenges may prevent it from capturing industry-wide growth, especially as competitors like Tetra Pak continue to scale in the same expanding market.